Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rufinamide in refractory partial seizures
NCT04558580Phase 3Withdrawn
- Sponsor
- University of South Alabama
- Start
- Apr 2006
- Primary completion
- Dec 2008
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rufinamide in focal-onset epileptic seizures, sponsored by University of South Alabama. Primary endpoint: Percentage change in total partial seizure frequency from baseline at 22 weeks. Planned start Apr 2006; status: withdrawn.
02
Drugs
rufinamide
03
Conditions
focal-onset epileptic seizures
Beyond the preview
Go deeper on NCT04558580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04558580.